Cargando…
Therapeutic implications of mitochondrial stress–induced proteasome inhibitor resistance in multiple myeloma
The connections between metabolic state and therapy resistance in multiple myeloma (MM) are poorly understood. We previously reported that electron transport chain (ETC) suppression promotes sensitivity to the BCL-2 antagonist venetoclax. Here, we show that ETC suppression promotes resistance to pro...
Autores principales: | Sharma, Aditi, Nair, Remya, Achreja, Abhinav, Mittal, Anjali, Gupta, Pulkit, Balakrishnan, Kamakshi, Edgar, Claudia L., Animasahun, Olamide, Dwivedi, Bhakti, Barwick, Benjamin G., Gupta, Vikas A., Matulis, Shannon M., Bhasin, Manoj, Lonial, Sagar, Nooka, Ajay K., Wiita, Arun P., Boise, Lawrence H., Nagrath, Deepak, Shanmugam, Mala |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for the Advancement of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519052/ https://www.ncbi.nlm.nih.gov/pubmed/36170375 http://dx.doi.org/10.1126/sciadv.abq5575 |
Ejemplares similares
-
Downregulation of PA28α induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma
por: Gu, Yanyan, et al.
Publicado: (2020) -
β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myeloma
por: Nair, Remya, et al.
Publicado: (2022) -
Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma
por: Bajpai, Richa, et al.
Publicado: (2020) -
Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax
por: Bajpai, R, et al.
Publicado: (2015) -
Mitochondrial metabolic determinants of multiple myeloma growth, survival, and therapy efficacy
por: Nair, Remya, et al.
Publicado: (2022)